AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11897644 — intervention group
Group type: COMPARATOR
Intervention: Conventional mechanical ventilation (CMV)
Number of subjects: 90
Study 11897644 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial liquid ventilation (PLV)
Number of subjects: 90
Study 10206118 — intervention group
Group type: EXPERIMENTAL
Intervention: MDT + 10 daily doses of 2 x 10(6) IU of recombinant human IFN-gamma/m2 followed by 10 daily doses of 10(7) IU IFN-gamma/m2
Number of subjects: 20
Study 10206118 — intervention group
Group type: COMPARATOR
Intervention: MDT alone
Number of subjects: 20
Study 10206118 — intervention group
Group type: EXPERIMENTAL
Intervention: MDT + IFN-gamma
Number of subjects: 20
Study 7540413 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibody B724
Number of subjects: 0
Study 7540413 — intervention group
Group type: COMPARATOR
Intervention: Control ELISAs using polyclonal antibodies
Number of subjects: 0
Study 2230890 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative intraarterial cisplatin (CDP) and surgery (TIOS I and III)
Number of subjects: 98
Study 2230890 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy only (TIOS II)
Number of subjects: 98
Study 2230890 — intervention group
Group type: EXPERIMENTAL
Intervention: Amputation
Number of subjects: 98
Study 2230890 — intervention group
Group type: EXPERIMENTAL
Intervention: Limb salvage
Number of subjects: 98
Study 2230890 — intervention group
Group type: COMPARATOR
Intervention: Tumor burden
Number of subjects: 98
Study 2230890 — intervention group
Group type: COMPARATOR
Intervention: Percentage of tumor necrosis induced by preoperative chemotherapy
Number of subjects: 98
Study 2230890 — intervention group
Group type: COMPARATOR
Intervention: Histopathologic subtype (chondroblastic vs osteoblastic)
Number of subjects: 98
Study 7150174 — intervention group
Group type: EXPERIMENTAL
Intervention: Benactyzine hydrochloride (4.14 mg/70 kg body weight)
Number of subjects: 12
Study 7150174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30935742 — intervention group
Group type: EXPERIMENTAL
Intervention: RZV
Number of subjects: 14645
Study 30935742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14645
Study 28163000 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus bevacizumab
Number of subjects: 1063
Study 28163000 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 1063
Study 27440682 — intervention group
Group type: EXPERIMENTAL
Intervention: Ficus carica paste
Number of subjects: 80
Study 27440682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 24957569 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-length colonoscope
Number of subjects: 1200
Study 24957569 — intervention group
Group type: COMPARATOR
Intervention: Intermediate-length colonoscope
Number of subjects: 1200
Study 23439606 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous training program (60%-79% HR max) for 8 weeks, 45-60 minutes, 3 times per week
Number of subjects: 217
Study 23439606 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control group
Number of subjects: 217
Study 20041249 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy
Number of subjects: 350
Study 20041249 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 350
Study 18663319 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (Genotropin) treatment at a median dose of 0.03 mg/kg/day for a median duration of 10.2 years (range 6.9-11.5)
Number of subjects: 22
Study 15958097 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan 2.5 mg
Number of subjects: 42
Study 15958097 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan 10 mg
Number of subjects: 42
Study 15958097 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 100 mg
Number of subjects: 42
Study 15958097 — intervention group
Group type: EXPERIMENTAL
Intervention: Almotriptan 12.5 mg
Number of subjects: 42
Study 15958097 — intervention group
Group type: EXPERIMENTAL
Intervention: Eletriptan 40 mg
Number of subjects: 42
Study 15958097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 12610038 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide 120 microg BID
Number of subjects: 656
Study 12610038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 656
Study 10608399 — intervention group
Group type: EXPERIMENTAL
Intervention: MultiHance (gadobenate dimeglumine, Gd‐BOPTA) administered at a dosage of 0.05 mmol/kg during the dynamic phase of contrast enhancement.
Number of subjects: 6
Study 8719517 — intervention group
Group type: EXPERIMENTAL
Intervention: Engerix-B (EB) 20 micrograms administered IM at 0, 1, 2, and 12 months
Number of subjects: 0
Study 8719517 — intervention group
Group type: COMPARATOR
Intervention: Recombivax HB (RHB) 10 micrograms administered IM at 0, 1, and 6 months
Number of subjects: 0
Study 8719517 — intervention group
Group type: EXPERIMENTAL
Intervention: Engerix-B (EB)
Number of subjects: 0
Study 8719517 — intervention group
Group type: COMPARATOR
Intervention: Recombivax HB (RHB)
Number of subjects: 0
Study 1837245 — intervention group
Group type: EXPERIMENTAL
Intervention: Niaprazine (1 mg/kg body weight)
Number of subjects: 36
Study 1837245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 6828120 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 66
Study 6828120 — intervention group
Group type: COMPARATOR
Intervention: Chlorothiazide
Number of subjects: 66
Study 30417225 — intervention group
Group type: COMPARATOR
Intervention: 14-day treatment with 10% carbamide peroxide gel applied for 2 hours a day
Number of subjects: 50
Study 30417225 — intervention group
Group type: EXPERIMENTAL
Intervention: 21-day treatment with 10% carbamide peroxide gel applied for 2 hours a day
Number of subjects: 50
Study 27801539 — intervention group
Group type: EXPERIMENTAL
Intervention: EEA stapler (Covidien)
Number of subjects: 135
Study 27801539 — intervention group
Group type: COMPARATOR
Intervention: PPH stapler (Ethicon EndoSurgery)
Number of subjects: 135
Study 25943679 — intervention group
Group type: EXPERIMENTAL
Intervention: Swimming in 33°C water (HA)
Number of subjects: 8
Study 25943679 — intervention group
Group type: COMPARATOR
Intervention: Swimming in 28°C water (CON)
Number of subjects: 8
Study 24421292 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid
Number of subjects: 572
Study 24421292 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher education
Number of subjects: 572
Study 24421292 — intervention group
Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 572
Study 24421292 — intervention group
Group type: COMPARATOR
Intervention: No confidence in completing forms
Number of subjects: 572
Study 24421292 — intervention group
Group type: COMPARATOR
Intervention: Poor self-reported health
Number of subjects: 572
Study 23127291 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal azelastine (AZE; 137 μg/spray)
Number of subjects: 610
Study 23127291 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fluticasone propionate (FP; 50 μg/spray)
Number of subjects: 610
Study 19200123 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein isolate (WPI) at 10% concentration and pH 2
Number of subjects: 0
Study 19200123 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein isolate (WPI) at 5% concentration and pH 2
Number of subjects: 0
Study 19200123 — intervention group
Group type: COMPARATOR
Intervention: Whey protein isolate (WPI) at varying concentrations (0%, 2.5%, 5%, and 10%) and pH levels (pH 2, 3, and 8)
Number of subjects: 0
Study 19200123 — intervention group
Group type: COMPARATOR
Intervention: Control (no WPI)
Number of subjects: 0
Study 17676256 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 26
Study 17676256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 17676256 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 26
Study 15020607 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus trastuzumab
Number of subjects: 247
Study 15020607 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 247
Study 15020607 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab alone or combined with palliative radiotherapy or hormonal therapy
Number of subjects: 247
Study 11842886 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphatidylserine (PS) supplementation 300 mg daily for one month
Number of subjects: 0
Study 9762483 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (walking-jogging)
Number of subjects: 39
Study 9762483 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower intensity exercise
Number of subjects: 39
Study 9762483 — intervention group
Group type: EXPERIMENTAL
Intervention: Training more than three times per week or for more than 50 minutes
Number of subjects: 39
Study 9762483 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 39
Study 8063359 — intervention group
Group type: EXPERIMENTAL
Intervention: Right nostril pranayama
Number of subjects: 48
Study 8063359 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate nostril pranayama
Number of subjects: 48
Study 8063359 — intervention group
Group type: EXPERIMENTAL
Intervention: Left nostril pranayama
Number of subjects: 48
Study 3058016 — intervention group
Group type: EXPERIMENTAL
Intervention: HPA-23 (ammonium-21-tungsto-9-antimoniate) at 0.25, 0.5, 1.0, or 2.0 mg/kg intravenously 5 days per week for 8 weeks
Number of subjects: 69
Study 3058016 — intervention group
Group type: EXPERIMENTAL
Intervention: HPA-23 (ammonium-21-tungsto-9-antimoniate)
Number of subjects: 69
Study 29859056 — intervention group
Group type: EXPERIMENTAL
Intervention: Under reporting of energy intake at study entry (10‐20 weeks gestation)
Number of subjects: 945
Study 29859056 — intervention group
Group type: EXPERIMENTAL
Intervention: Under reporting of energy intake at 36 weeks gestation
Number of subjects: 945
Study 29859056 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate reporters at study entry
Number of subjects: 945
Study 29859056 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate reporters at 36 weeks gestation
Number of subjects: 945
Study 29859056 — intervention group
Group type: EXPERIMENTAL
Intervention: Over reporters at study entry
Number of subjects: 945
Study 29859056 — intervention group
Group type: EXPERIMENTAL
Intervention: Over reporters at 36 weeks gestation
Number of subjects: 945
Study 29859056 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent predictors of under reporting of energy intake
Number of subjects: 945
Study 28391236 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsolicited infectious disease consultant (IDC) counselling
Number of subjects: 500
Study 28391236 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 500
Study 25893283 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based early intervention (8 home visits from community nurses)
Number of subjects: 465
Study 25893283 — intervention group
Group type: COMPARATOR
Intervention: Control group (no further intervention)
Number of subjects: 465
Study 25893283 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based early intervention
Number of subjects: 465
Study 25893283 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 465
Study 24649767 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitaprost Plus
Number of subjects: 0
Study 24649767 — intervention group
Group type: COMPARATOR
Intervention: Lomflox
Number of subjects: 0
Study 21982727 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg three times daily)
Number of subjects: 120
Study 21982727 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets (three times daily)
Number of subjects: 120
Study 18775597 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal metronidazole (2x 1000 mg pessaries 24h apart)
Number of subjects: 263
Study 18775597 — intervention group
Group type: COMPARATOR
Intervention: Oral metronidazole (1 x 2000 mg tablets)
Number of subjects: 263
Study 18775597 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal metronidazole
Number of subjects: 263
Study 18775597 — intervention group
Group type: COMPARATOR
Intervention: Oral metronidazole
Number of subjects: 263
Study 15932378 — intervention group
Group type: EXPERIMENTAL
Intervention: Impermeable encasings for mattress, pillow and duvet
Number of subjects: 224
Study 15932378 — intervention group
Group type: COMPARATOR
Intervention: Nonimpermeable encasings for mattress, pillow and duvet
Number of subjects: 224
Study 12872393 — intervention group
Group type: EXPERIMENTAL
Intervention: CT positioning scalp circum-needling (SCN) combined with Chinese herbal medicine (Fuyuan mixture)
Number of subjects: 89
Study 12872393 — intervention group
Group type: COMPARATOR
Intervention: Control group (Fuyuan mixture only)
Number of subjects: 89
Study 12872393 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (SCN + FYM and FYM only)
Number of subjects: 89
Study 10561764 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial off catheter
Number of subjects: 79
Study 10561764 — intervention group
Group type: COMPARATOR
Intervention: Trial off catheter 24 hours after admission
Number of subjects: 79
Study 8885761 — intervention group
Group type: EXPERIMENTAL
Intervention: ephedrine sulfate
Number of subjects: 50
Study 8885761 — intervention group
Group type: COMPARATOR
Intervention: normal saline solution
Number of subjects: 50
Study 1947469 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cytosine arabinoside combined with dexamethasone and cisplatinum
Number of subjects: 43
Study 1947469 — intervention group
Group type: COMPARATOR
Intervention: Low-dose cytosine arabinoside combined with dexamethasone and cisplatinum
Number of subjects: 43
Study 6339110 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 280
Study 6339110 — intervention group
Group type: COMPARATOR
Intervention: Quinidine
Number of subjects: 280
Study 31389731 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin 4 mg/kg/d for 3 months
Number of subjects: 32
Study 31389731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 31212940 — intervention group
Group type: EXPERIMENTAL
Intervention: HiEAAs (specially-formulated composition of essential amino acids)
Number of subjects: 0
Study 31212940 — intervention group
Group type: COMPARATOR
Intervention: LoEAA (commercially popular protein-based meal replacement beverage)
Number of subjects: 0
Study 30073679 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded estimators for within and between person variances
Number of subjects: 0
Study 30073679 — intervention group
Group type: COMPARATOR
Intervention: Unblinded approach
Number of subjects: 0
Study 27193374 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen-specific immunotherapy (ASIT)
Number of subjects: 205
Study 27193374 — intervention group
Group type: COMPARATOR
Intervention: No treatment (untreated group)
Number of subjects: 205
Study 25037883 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous growth hormone injection (3 mg/24 h) during exercise (1 hour bicycling with 50 W load)
Number of subjects: 8
Study 25037883 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous growth hormone injection (3 mg/24 h) during supine rest
Number of subjects: 8
Study 25037883 — intervention group
Group type: COMPARATOR
Intervention: Continuous subcutaneous growth hormone infusion (3 mg/24 h)
Number of subjects: 8
Study 23176112 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injections
Number of subjects: 109
Study 23176112 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic Acid (HA) injections
Number of subjects: 109
Study 20103234 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercostal muscle flap and intracostal sutures
Number of subjects: 120
Study 20103234 — intervention group
Group type: COMPARATOR
Intervention: Usual pericostal sutures
Number of subjects: 120
Study 16804691 — intervention group
Group type: EXPERIMENTAL
Intervention: Low alcohol dose (two to three drinks equivalent)
Number of subjects: 39
Study 16804691 — intervention group
Group type: EXPERIMENTAL
Intervention: High alcohol dose (four to five drinks equivalent)
Number of subjects: 39
Study 16804691 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1% volume alcohol as a taste mask)
Number of subjects: 39
Study 14519178 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual probe task with smoking cues
Number of subjects: 141
Study 10714423 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled glucocorticosteroids (IGC), 250 microg of fluticasone propionate (FP) twice a day for 8 weeks
Number of subjects: 67
Study 10714423 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group) for 8 weeks
Number of subjects: 67
Study 10714423 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled glucocorticosteroids (IGC)
Number of subjects: 67
Study 8881621 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane 0.4‐1.2 vol%
Number of subjects: 49
Study 8881621 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 3‐5 mg kg‐1 h‐1 i.v.
Number of subjects: 49
Study 8881621 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold value of SEF 14 Hz
Number of subjects: 49
Study 1307881 — intervention group
Group type: EXPERIMENTAL
Intervention: Room-temperature thermodilution cardiac output measurements from the right ventricular port
Number of subjects: 37
Study 3884128 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (A) 60 mg/m2
Number of subjects: 104
Study 3884128 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin 60 mg/m2 and cyclophosphamide 500 mg/m2 (CA)
Number of subjects: 104
Study 3884128 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (A) 60 mg/m2 and Doxorubicin 60 mg/m2 and cyclophosphamide 500 mg/m2 (CA)
Number of subjects: 104
Study 31951279 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab 162 mg weekly
Number of subjects: 36
Study 30198644 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia (TIVA)
Number of subjects: 30
Study 30198644 — intervention group
Group type: COMPARATOR
Intervention: Inhaled desflurane
Number of subjects: 30
Study 27575012 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic kinesiology taping (KT)
Number of subjects: 44
Study 27575012 — intervention group
Group type: COMPARATOR
Intervention: Sham kinesiology taping (KT)
Number of subjects: 44
Study 27575012 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder sonography
Number of subjects: 44
Study 25435604 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabegon (4 gm daily)
Number of subjects: 58
Study 23059927 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA therapy suspended for seven days before tooth extraction
Number of subjects: 0
Study 23059927 — intervention group
Group type: COMPARATOR
Intervention: ASA therapy continued without suspension
Number of subjects: 0
Study 19926383 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-inflating bag (SI-bag)
Number of subjects: 120
Study 19926383 — intervention group
Group type: COMPARATOR
Intervention: T-piece resuscitator
Number of subjects: 120
Study 18549489 — intervention group
Group type: EXPERIMENTAL
Intervention: Visiting service for older widowed individuals
Number of subjects: 110
Study 18549489 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 110
Study 15817872 — intervention group
Group type: EXPERIMENTAL
Intervention: soy protein isolate enriched with isoflavones (soy‐plus diet)
Number of subjects: 15
Study 15817872 — intervention group
Group type: EXPERIMENTAL
Intervention: soy protein isolate devoid of isoflavones (soy‐minus diet)
Number of subjects: 15
Study 15817872 — intervention group
Group type: COMPARATOR
Intervention: casein‐whey protein isolate (control diet)
Number of subjects: 15
Study 15817872 — intervention group
Group type: EXPERIMENTAL
Intervention: soy‐minus diet
Number of subjects: 15
Study 12091332 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive-timing induction
Number of subjects: 24
Study 12091332 — intervention group
Group type: COMPARATOR
Intervention: Standard-timing induction
Number of subjects: 24
Study 12091332 — intervention group
Group type: EXPERIMENTAL
Intervention: tMDS/tAML
Number of subjects: 24
Study 12091332 — intervention group
Group type: COMPARATOR
Intervention: De novo MDS/AML
Number of subjects: 24
Study 10599711 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone treatment (GH) discontinued after 2 years
Number of subjects: 40
Study 7805898 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% CO2/90% N2/5% O2 (low oxygen)
Number of subjects: 186
Study 7805898 — intervention group
Group type: COMPARATOR
Intervention: 5% CO2/95% air (20% O2) (ambient oxygen)
Number of subjects: 186
Study 7805898 — intervention group
Group type: EXPERIMENTAL
Intervention: Low oxygen (mouse embryos)
Number of subjects: 186
Study 7805898 — intervention group
Group type: COMPARATOR
Intervention: Ambient oxygen (mouse embryos)
Number of subjects: 186
Study 1769866 — intervention group
Group type: EXPERIMENTAL
Intervention: Ems brine inhalations (200 ml, 3 times a day for 10 days)
Number of subjects: 30
Study 1769866 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (200 ml, 3 times a day for 10 days)
Number of subjects: 30
Study 7140799 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine 60 mg
Number of subjects: 12
Study 7140799 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine 180 mg
Number of subjects: 12
Study 7140799 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine 25 mg
Number of subjects: 12
Study 7140799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31335881 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF inhibitor alone (n = 25)
Number of subjects: 51
Study 31335881 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF inhibitor combined with methotrexate (MTX) (n = 10)
Number of subjects: 51
Study 31335881 — intervention group
Group type: COMPARATOR
Intervention: MTX monotherapy (n = 16)
Number of subjects: 51
Study 28161306 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (n=150): cycling exercise 3 times per week, at least 30 min/session, initiated within 3 days of randomization until 37 weeks of gestation.
Number of subjects: 300
Study 28161306 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (n=150)
Number of subjects: 300
Study 28161306 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=150)
Number of subjects: 300